FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3124726691> ?p ?o ?g. }

• W3124726691 endingPage "512" @default.
• W3124726691 startingPage "504" @default.
• W3124726691 abstract "Abstract Adolescents and young adults (AYAs) with acute lymphoblastic leukemia have improved outcomes when treated with pediatric-inspired regimens. CALGB 10403 was the largest prospective study to evaluate the feasibility of using a pediatric regimen in AYAs with acute lymphoblastic leukemia up to 40 years of age. This article presents the toxicity events observed in the CALGB 10403 study and compares these toxicities vs those observed among AYAs treated on the same arm of the companion Children’s Oncology Group (COG) AALL0232 study. Toxicities in CALGB 10403 were similar to those observed in COG AALL0232. Some grade 3 to 4 adverse events were more often reported in CALGB 10403 compared with COG AALL0232 (hyperglycemia, hyperbilirubinemia, transaminase elevation, and febrile neutropenia). Adverse events correlated with body mass index ≥30 kg/m2 and some with increasing age. The mortality rate in CALGB 10403 was low (4%) and similar to that in the COG AALL0232 trial. A caveat to this analysis is that only 39% of CALGB 10403 patients completed all planned protocol treatment. In COG AALL0232, although 74% of patients aged &lt;18 years completed treatment, only 57% of patients aged ≥18 years completed treatment. This scenario suggests that issues associated with age and treating physician may be a factor. Due to its improved survival rates compared with historical controls, the CALGB 10403 regimen is now a standard of care. The hope is that the rate of protocol completion will increase as more familiarity is gained with this regimen. These trials were registered at www.clinicaltrials.gov as #NCT00558519 (CALGB 10403) and #NCT00075725 (COG AALL0232)." @default.
• W3124726691 created "2021-02-01" @default.
• W3124726691 creator A5001124933 @default.
• W3124726691 creator A5004302802 @default.
• W3124726691 creator A5005939966 @default.
• W3124726691 creator A5010840699 @default.
• W3124726691 creator A5011144900 @default.
• W3124726691 creator A5014838335 @default.
• W3124726691 creator A5015357573 @default.
• W3124726691 creator A5023214494 @default.
• W3124726691 creator A5024573751 @default.
• W3124726691 creator A5031561153 @default.
• W3124726691 creator A5050556099 @default.
• W3124726691 creator A5054336817 @default.
• W3124726691 creator A5056405520 @default.
• W3124726691 creator A5056916024 @default.
• W3124726691 creator A5063929028 @default.
• W3124726691 creator A5070141658 @default.
• W3124726691 creator A5071023119 @default.
• W3124726691 creator A5072420982 @default.
• W3124726691 creator A5080485119 @default.
• W3124726691 creator A5082944296 @default.
• W3124726691 creator A5083159737 @default.
• W3124726691 creator A5085010022 @default.
• W3124726691 creator A5085783292 @default.
• W3124726691 date "2021-01-22" @default.
• W3124726691 modified "2023-10-16" @default.
• W3124726691 title "Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia" @default.
• W3124726691 cites W1966375226 @default.
• W3124726691 cites W1971341070 @default.
• W3124726691 cites W2013104538 @default.
• W3124726691 cites W2052739233 @default.
• W3124726691 cites W2073255871 @default.
• W3124726691 cites W2106275447 @default.
• W3124726691 cites W2134892517 @default.
• W3124726691 cites W2145662640 @default.
• W3124726691 cites W2157438100 @default.
• W3124726691 cites W2342769258 @default.
• W3124726691 cites W2402309410 @default.
• W3124726691 cites W2560297230 @default.
• W3124726691 cites W2745522463 @default.
• W3124726691 cites W2772927421 @default.
• W3124726691 cites W2790444073 @default.
• W3124726691 cites W2892578575 @default.
• W3124726691 cites W2908746540 @default.
• W3124726691 cites W2939150686 @default.
• W3124726691 cites W2983476584 @default.
• W3124726691 cites W3000547742 @default.
• W3124726691 doi "https://doi.org/10.1182/bloodadvances.2020002439" @default.
• W3124726691 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7839367" @default.
• W3124726691 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33496745" @default.
• W3124726691 hasPublicationYear "2021" @default.
• W3124726691 type Work @default.
• W3124726691 sameAs 3124726691 @default.
• W3124726691 citedByCount "18" @default.
• W3124726691 countsByYear W31247266912021 @default.
• W3124726691 countsByYear W31247266912022 @default.
• W3124726691 countsByYear W31247266912023 @default.
• W3124726691 crossrefType "journal-article" @default.
• W3124726691 hasAuthorship W3124726691A5001124933 @default.
• W3124726691 hasAuthorship W3124726691A5004302802 @default.
• W3124726691 hasAuthorship W3124726691A5005939966 @default.
• W3124726691 hasAuthorship W3124726691A5010840699 @default.
• W3124726691 hasAuthorship W3124726691A5011144900 @default.
• W3124726691 hasAuthorship W3124726691A5014838335 @default.
• W3124726691 hasAuthorship W3124726691A5015357573 @default.
• W3124726691 hasAuthorship W3124726691A5023214494 @default.
• W3124726691 hasAuthorship W3124726691A5024573751 @default.
• W3124726691 hasAuthorship W3124726691A5031561153 @default.
• W3124726691 hasAuthorship W3124726691A5050556099 @default.
• W3124726691 hasAuthorship W3124726691A5054336817 @default.
• W3124726691 hasAuthorship W3124726691A5056405520 @default.
• W3124726691 hasAuthorship W3124726691A5056916024 @default.
• W3124726691 hasAuthorship W3124726691A5063929028 @default.
• W3124726691 hasAuthorship W3124726691A5070141658 @default.
• W3124726691 hasAuthorship W3124726691A5071023119 @default.
• W3124726691 hasAuthorship W3124726691A5072420982 @default.
• W3124726691 hasAuthorship W3124726691A5080485119 @default.
• W3124726691 hasAuthorship W3124726691A5082944296 @default.
• W3124726691 hasAuthorship W3124726691A5083159737 @default.
• W3124726691 hasAuthorship W3124726691A5085010022 @default.
• W3124726691 hasAuthorship W3124726691A5085783292 @default.
• W3124726691 hasBestOaLocation W31247266911 @default.
• W3124726691 hasConcept C126322002 @default.
• W3124726691 hasConcept C154945302 @default.
• W3124726691 hasConcept C187212893 @default.
• W3124726691 hasConcept C197934379 @default.
• W3124726691 hasConcept C205545832 @default.
• W3124726691 hasConcept C2777063308 @default.
• W3124726691 hasConcept C2778461978 @default.
• W3124726691 hasConcept C2781107101 @default.
• W3124726691 hasConcept C2781413609 @default.
• W3124726691 hasConcept C2909962599 @default.
• W3124726691 hasConcept C29730261 @default.
• W3124726691 hasConcept C41008148 @default.
• W3124726691 hasConcept C4661277 @default.
• W3124726691 hasConcept C71924100 @default.
• W3124726691 hasConceptScore W3124726691C126322002 @default.

• next